glp-1 drugs cancer weight-loss are transforming lives — but what do they really mean for people facing cancer? We brought together perspectives from researchers, clinicians and patients navigating the promise and the tradeoffs GLP-1 drugs may have a

In the LEADER trial, 3.1% of Victoza -treated patients versus 1.9% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis

Our findings have potential to be relevant when considering prescribing choices to lower ICP, since exenatide seemingly avoids further impairment of cognition

Secondary Benefits GLP-1 drugs also appear to have some extra benefits

Between 65% and 96% of participants taking orforglipron achieved an A1C level below 7.0% at 26 weeks

Patients taking concomitant diabetes medications should monitor their blood sugars closely and be prepared to treat hypoglycemia if needed (see hypoglycemia for more)